CLINICAL
RESEARCH
Acemannan hydrogel’s safety and efficacy are supported by years of publications and clinical studies.
AceTech is continuously conducting clinical and pre-clinical studies to uncover new benefits of our products and to further develop our prediction technology.We are committed to conducting all of our research activities according to Good Clinical Practice (GCP) guidelines ensuring high quality and reliable results.
ASSUTA MEDICAL CENTER
RadiaAce Hydrogel has Proven to Reduce the Proportion of Patients Suffering from High-grade Radiation Dermatitis
Assuta Hospital, Radiotherapy unit. Tel-Aviv, Israel.
Proportion of patients with maximal RTOG ≥2 score
RadiaAce reduced the proportion of breast cancer patients with maximal RTOG ≥2 score by 15% compared to gold standard
• The clinical results showed a significant reduction in favor of RadiaAce in the proportion of patients experiencing severe radiation induced skin reactions.
• The proportion of patients experiencing high grade radiation induced skin reactions was 15% lower among patients who were treated with RadiaAce as compared to gold standard/standard of care.
Proportion of patients with RTOG ≥2 during radiation treatment
RadiaAce was found to be 1.6 times effective in reducing high-grade radiation dermatitis two weeks after radiation treatment
RAMBAM HOSPITAL
Does skin microbiome affect the occurrence and severity of Radiation Dermatitis in breast cancer patients?
Rambam Hospital, Radiotherapy unit. Haifa, Israel.
This observational study was conducted at Ramabm Medical Center and included 100 female breast cancer patients going through radiation therapy. This innovative study explored the skin microbiome profile of the patients and its correlation to Radiation Dermatitis severity developed by the patients. We found a bacterial signature that is associated with a significantly higher risk for severe dermatitis.